We announce the 10th Annual
RNA Therapeutics Conference in London on February 20th - 21st 2019.
The field of
RNA therapeutics is currently undergoing a major expansion, and the potential for using
RNA drugs for personalised medicines and immunotherapy, as well as to address genetic, infectious and chronic diseases will ensure the continued development of
RNA therapeutics for years to come.
Join us in February 2019, as our
RNA Therapeutics Conference brings together industry experts from leading
RNA therapeutics companies to discuss the challenges for clinical translation of
RNA-based therapeutics, with an emphasis on recent advances in delivery technologies, and present an overview of the applications of
RNA-based drugs for modulation of gene and protein expression, and genome editing.
Benefits of Attending
- Discover the clinical progress of Spherical Nucleic Acids at Exicure
- Understand Sanofi's strategies to deliver therapeutic oligonucleotides across biobarriers
- Learn from ProQR how to plan for oligonucleotide supply from personalized medicine to large scale markets
- Explore the development of small activating RNA - from bench to bedside with MiNA Therapeutics
- Gain insight into the discovery and development of self-amplifying mRNA vaccines at GSK
Who should attend
Key Job Titles include:
- Research & Development Directors/Managers/Scientists
- Senior Scientists
- Chief Scientific Officers
- Chief Medical Officers
- Heads of Clinical Development
- Heads of Pre-Clinical Development
Speakers
- Ali Murad, Director, Alnylam Pharmaceuticals UK & Ireland
- Andre Gerber, Professor, RNA Biology, University Of Surrey
- Bob Brown, Chief Scientific Officer, Senior Vice President, Dicerna Pharmaceuticals Inc.
- Carsten Rudolf, Chief Executive Officer, Ethris GmbH
- Christoph Rosenbohm, Head of Discovery Operations, Roche Innovation Center
- Daniel Zucker, Business Development Manager, NOF Europe GmbH
- David Blakey, Chief Scientific Officer, MiNA Therapeutics
- David Giljohann, CEO, Exicure Inc.
- Ekkehard Leberer, Senior Director , Sanofi-Aventis Deutschland GmbH
- Hans Kistemaker, Associate Director, ProQR
- Henrich Haas, Vice President RNA Formulation & Drug Delivery, BioNTech RNA Pharmaceuticals
- Ingmar Hoerr, Founder and CEO, Curevac Ag
- Jeffrey Ulmer, Head Preclinical R&D, GSK
- Kai Wilkens, Senior Director Europe ACD, Advanced Cell Diagnostics SRL
- Kirsty Wydenbach, Deputy Unit Manager, Clinical Trials Unit, MHRA
- Marian Gindy, Executive Director, MSD
- Markus Mandler, Chief Scientific Officer, Accanis Biotech F&E GmbH & Co KG
- Paul Agris, Director, The RNA Institute
- Shalini Andersson, Senior Director and Head of New Modalities, AstraZeneca
- Steffen Panzner, Managing Director, Lipocalyx
Please fill in your name and email to receive the Conference Agenda of this event.
Venue
Copthorne Tara Hotel
Scarsdale Pl, Kensington, W8 5SY
London, UK
Venue
Copthorne Tara HotelScarsdale Place, Kensington
London, United Kingdom
